Add to ORKGThis review includes another types of treatments of the hyperlipidemia. The first part of this review is for the classic treatments for hyperlipidemia; statin, and non-statin classic drugs, such as resin, ezetimibe, niacin, and fibrate. The second part is for New advanced approaches in the treatments of the hyperlipidemia, including CETP Inhibitor, MTTP Inhibitor, PCSK9 Inhibitor, Bempedoic acid, Gemcabene, and dual PPAR Modulator.egységes, osztatlanáltalános orvosango
Atherosclerosis, the underlying process that ultimately leads to clinical cardiovascular disease (CV...
Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has con...
Hypercholesterolemia is considered as one of the most important risk factors and thereby a primary t...
clinical presentation, diagnosis, pathophysiology, and newly selected drugs: PCSK9 inhibitors, CETP...
Dyslipidaemia is a well-known risk factor for the development of cardiovascular disease, a leading c...
Hyperlipidemia is a major risk factor for the development of cardiovascular disease. Considerable ev...
Hypercholesterolemia affects over 34 million adults in the United States and is a major cause of cor...
Importance of the field: Lipid-modifying drugs are therapeutic options that have been shown to reduc...
none3noDespite the consolidated role of statins and ezetimibe to treat hypercholesterolemia, often t...
Cardiovascular disease (CVD) remains a major cause of death worldwide, with dyslipidaemia playing a ...
Coronary heart disease (CHD) is a major cause of morbidityand mortality. Recent evidence supports th...
Despite the demonstrated benefits of statins and injectable biologics, there is a need for new and s...
The article deals with the management of patients with dislipidemias and modern approaches to their ...
Hyperlipidemia is a well-established risk factor for atherogenesis and cardiovascular disease. Stati...
Atherosclerotic disease remains the leading cause of death worldwide. Much of atherosclerotic diseas...
Atherosclerosis, the underlying process that ultimately leads to clinical cardiovascular disease (CV...
Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has con...
Hypercholesterolemia is considered as one of the most important risk factors and thereby a primary t...
clinical presentation, diagnosis, pathophysiology, and newly selected drugs: PCSK9 inhibitors, CETP...
Dyslipidaemia is a well-known risk factor for the development of cardiovascular disease, a leading c...
Hyperlipidemia is a major risk factor for the development of cardiovascular disease. Considerable ev...
Hypercholesterolemia affects over 34 million adults in the United States and is a major cause of cor...
Importance of the field: Lipid-modifying drugs are therapeutic options that have been shown to reduc...
none3noDespite the consolidated role of statins and ezetimibe to treat hypercholesterolemia, often t...
Cardiovascular disease (CVD) remains a major cause of death worldwide, with dyslipidaemia playing a ...
Coronary heart disease (CHD) is a major cause of morbidityand mortality. Recent evidence supports th...
Despite the demonstrated benefits of statins and injectable biologics, there is a need for new and s...
The article deals with the management of patients with dislipidemias and modern approaches to their ...
Hyperlipidemia is a well-established risk factor for atherogenesis and cardiovascular disease. Stati...
Atherosclerotic disease remains the leading cause of death worldwide. Much of atherosclerotic diseas...
Atherosclerosis, the underlying process that ultimately leads to clinical cardiovascular disease (CV...
Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has con...
Hypercholesterolemia is considered as one of the most important risk factors and thereby a primary t...